statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced...

VBI Vaccines Reports Full Year 2023 Financial Results

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously...

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into...

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV - Get Free Report) in a report released on Tuesday. The firm set a "sell" rating on the biopharmaceutical company's stock. VBI...

VBI Vaccines (NASDAQ:VBIV) Now Covered by StockNews.com

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

VBI Vaccines presents data from Phase 2b study of VBI-1901

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D...

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has...

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV  Free Report) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical companys...

VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results PR Newswire DURHAM...

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV  Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the...

StockNews.com Initiates Coverage on VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Volume	113,638.00
52-Wk High	$3.47
52-Wk Low	$0.45

VBIV VBI Vaccines Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals